Erasca (ERAS) Shares Outstanding (Diluted Average) (2021 - 2026)
Erasca (ERAS) reported Shares Outstanding (Diluted Average) of $304.3 million for Q1 2026, up 7.43% on a YoY basis from $283.3 million in Q1 2025, and up 7.33% quarter-over-quarter from $283.5 million in Q4 2025.
Erasca (ERAS) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
Erasca has reported Shares Outstanding (Diluted Average) for 6 years, with the latest figure at $304.3 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 7.43% year-over-year to $304.3 million; the trailing twelve-month figure through Mar 2026 stood at $304.3 million (up 7.43% YoY), and the FY2025 full-year result was $283.5 million, up 21.26% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $304.3 million, up from $283.5 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $304.3 million in Q1 2026, with the low at $119.5 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $196.5 million across 5 years, with a median of $151.2 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) surged 410.46% — and 2024, when it advanced 1.11%.
- Erasca's Shares Outstanding (Diluted Average) stood at $122.0 million in 2022, then increased by 23.08% to $150.2 million in 2023, then surged by 55.69% to $233.8 million in 2024, then gained by 21.26% to $283.5 million in 2025, then increased by 7.33% to $304.3 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $304.3 million (Q1 2026), $283.5 million (Q4 2025), and $283.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | 304.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 304.32 Mn |
| Dec 31, 2025 | 283.53 Mn |
| Sep 30, 2025 | 283.43 Mn |
| Jun 30, 2025 | 283.36 Mn |
| Mar 31, 2025 | 283.26 Mn |
| Dec 31, 2024 | 233.82 Mn |
| Sep 30, 2024 | 217.36 Mn |
| Jun 30, 2024 | 217.81 Mn |
| Mar 31, 2024 | 151.16 Mn |
| Dec 31, 2023 | 150.18 Mn |
| Sep 30, 2023 | 150.45 Mn |
| Jun 30, 2023 | 149.77 Mn |
| Mar 31, 2023 | 149.50 Mn |
| Dec 31, 2022 | 122.02 Mn |
| Sep 30, 2022 | 120.17 Mn |
| Jun 30, 2022 | 120.19 Mn |
| Mar 31, 2022 | 119.49 Mn |
| Dec 31, 2021 | 66.29 Mn |
| Sep 30, 2021 | 48.58 Mn |
| Jun 30, 2021 | 23.55 Mn |